Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenuePayablesPreferred Stock LiabilitiesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Drugs Made In America Acquisition (DMAA) Non-Current Deffered Revenue (2025)

Drugs Made In America Acquisition filings provide 1 years of Non-Current Deffered Revenue readings, the most recent being $6.9 million for Q4 2025.

  • Quarterly Non-Current Deffered Revenue changed N/A to $6.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.9 million through Dec 2025, changed N/A year-over-year, with the annual reading at $6.9 million for FY2025, N/A changed from the prior year.
  • Non-Current Deffered Revenue hit $6.9 million in Q4 2025 for Drugs Made In America Acquisition, roughly flat from $6.9 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $6.9 million in Q1 2025 and bottomed at $6.9 million in Q1 2025.